Viehbacher argues that the Memorial Sloan-Kettering doctors are wrong, and that Zaltrap is worth the money.
FORBES: Sanofi's CEO On The New York Times' Criticism Of Drug Prices And Surviving The Patent Cliff
2.
The Food and Drug Administration just announced that it approved Zaltrap for colorectal cancer, giving Tarrytown, N.
FORBES: Why Regeneron May Not Profit Much From Today's FDA Approval
3.
Memorial Sloan-Kettering Cancer Center in New York wrote an editorial in The New York Times how they refused to use the colon cancer medicine Zaltrap because it was priced much higher than another drug, but without offering additional benefit.